STIMOLA CURIOSITA’, PASSIONE E CORAGGIO
Proteoglycan-4 as coadjuvant treatment to overcome resistance to sorafenib and Regorafenib in patients with Hepatocellular carcinoma
Abstract
Sorafenib and regorafenib are the drugs most commonly used in patients with hepatocellular carcinoma (HCC), providing a disease control rate of approximately 40% of cases. Nevertheless, 30% of patients develop resistance to treatment.
Recently, we have demonstrated that an extracellular matrix component, named Proteoglycan-4 (PRG4), physiologically present in the body, works as a novel tumor-suppressive agent by strengthening sorafenib and regorafenib effects in "in vitro" models of HCC. Based on this finding, we have deposited a patent for the development of PRG4 as an adjuvant agent to overcome resistance to Sorafenib and Regorafenib. This project aims to develop the scientific prototype as follows: 1) to investigate the effectiveness of PRG4 in combination with Sorafenib and Regorafenib in in vivo models; 2) to investigate the effectiveness of PRG4 on immune cells infiltrating HCC; 3) to individuate the shorter aminoacidic sequence mimicking the PRG4 adjuvant effectiveness.
Partenariato
- Ente Ospedaliero specializzato in gastroenterologia Saverio De Bellis
- IRCCS Humanitas Research Hospital
- Biogem scarl
- Università degli Studi di Udine
Importo del progetto
Importo totale del progetto Euro 1.183.000,00
Importo del progetto Uniud Euro 246.000,00
Finanziamento Uniud Euro 0,00
Durata
- Dal 31.08.2024
- Al 30.08.2026
Link